Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

No abstract is available for this paper.

• Publication year

  2015

• Venue

  PROTEOMICS - Clinical Applications

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/prca.201400178PMID 25676562PMCID PMC4739636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fatty acid binding proteins and the nervous system: Their impact on mental conditions.

  2016cited by this paper
• Depression in informal caregivers of persons with dementia.

  2015cited by this paper
• Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

  2014cited by this paper
• Biobanking of CSF: international standardization to optimize biomarker development.

  2014cited by this paper
• Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies

  2014cited by this paper
• An Exploratory Study of Grief and Health-Related Quality of Life for Caregivers of People With Dementia

  2014cited by this paper
• Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease

  2013cited by this paper
• Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

  2013cited by this paper
• Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration

  2013cited by this paper
• Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins

  2013cited by this paper
• Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry

  2013cited by this paper
• Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

  2012cited by this paper
• A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid.

  2012cited by this paper
• Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins

  2012cited by this paper
• Recent advances in multiplex immunoassays.

  2012cited by this paper
• Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease.

  2012cited by this paper
• Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

  2012cited by this paper
• LC-MS/MS in the Clinical Laboratory - Where to From Here?

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• National estimates of the prevalence of Alzheimer's disease in the United States

  2011cited by this paper
• Linking lipids to Alzheimer's disease: cholesterol and beyond

  2011cited by this paper
• Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers

  2011cited by this paper
• The human fatty acid-binding protein family: Evolutionary divergences and functions

  2011cited by this paper
• Linking lipids to Alzheimer's disease: cholesterol and beyond

  2011cited by this paper
• Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

  2011cited by this paper
• Protein microarrays and novel detection platforms

  2011cited by this paper
• Aptamer-based multiplexed proteomic technology for biomarker discovery

  2010cited by this paper
• Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases

  2010cited by this paper
• Comparing predictors of conversion and decline in mild cognitive impairment

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry.

  2010cited by this paper
• Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding

  2009cited by this paper
• Relationships between biomarkers in aging and dementia

  2009cited by this paper
• Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype

  2009cited by this paper
• Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

  2009cited by this paper
• Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

  2009cited by this paper
• Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

  2009cited by this paper
• Selected reaction monitoring for quantitative proteomics: a tutorial

  2008cited by this paper
• PET imaging of amyloid deposition in patients with mild cognitive impairment.

  2008cited by this paper
• CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

  2007cited by this paper
• Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.

  2007cited by this paper
• CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

  2007cited by this paper
• Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

  2007cited by this paper
• CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

  2006cited by this paper
• Protein biomarker discovery and validation: the long and uncertain path to clinical utility

  2006cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Bioconductor: open software development for computational biology and bioinformatics

  2004influential reference
• Processing, Distribution, and Function of VGF, a Neuronal and Endocrine Peptide Precursor

  2004cited by this paper
• Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

  2003cited by this paper
• Statistical issues in cDNA microarray data analysis.

  2003influential reference
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

  2003cited by this paper
• Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule?

  2002cited by this paper
• Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

  2001cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Comparison of VGF and trk mRNA distributions in the developing and adult rat nervous systems.

  1997cited by this paper
• Atrophy of the hippocampus, parietal cortex, and insula in Alzheimer's disease: a volumetric magnetic resonance imaging study.

  1997cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation.

  1979cited by this paper
• Spectral mapping, a technique for classifying biological activity profiles of chemical compounds.

  1976cited by this paper
• Spectral mapping, a technique for classifying biological activity profiles of chemical compounds.

  1976influential reference
• The scope of mass spectrometry in clinical chemistry.

  1975cited by this paper
• Molecular Neurodegeneration Apolipoprotein E Levels in Cerebrospinal Fluid and the Effects of Abca1 Polymorphisms

  year unknowncited by this paper

• Astrocyte–vascular interplay in Alzheimer's disease pathology: Novel insights into stage‐specific biomarkers and therapeutic targets

  2026cites this paper
• Development of highly multiplex targeted proteomics assays in biofluids using a nominal mass ion trap mass spectrometer.

  2026cites this paper
• Integrating imaging and omics for enhanced subtyping of mild cognitive impairment associated with Alzheimer’s disease

  2025cites this paper
• Integrative analysis of proteomic and MRI data reveals protein associations with brain imaging features in Alzheimer’s disease

  2025cites this paper
• Cerebrospinal fluid neuronal pentraxin levels are associated with tau pathology via microglia–astrocyte signaling in alzheimer’s disease

  2025cites this paper
• Cognitive resilience in preclinical Alzheimer's disease: Higher NPTX2 and VGF levels are associated with reduced cognitive decline.

  2025cites this paper
• Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases

  2025cites this paper
• Complement C1q is associated with neuroinflammation and mediates the association between amyloid-β and tau pathology in Alzheimer’s disease

  2025cites this paper
• Associations between fluid biomarkers and PET imaging ([11C]UCB‐J) of synaptic pathology in Alzheimer's disease

  2025cites this paper
• Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome

  2025cites this paper
• Isoforms of Phosphorylated Tau as Potential Biomarkers for Alzheimer’s Disease: The Contribution of Mass Spectrometry-Based Proteomics

  2025cites this paper
• A compilation of reported alterations in the cerebrospinal fluid proteome in Alzheimer's disease

  2025cites this paper
• Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer.

  2025cites this paper
• ProSAAS neuropeptides and receptors GPR171 and GPR83: Potential therapeutic applications for pain, anxiety, and body weight regulation.

  2025cites this paper
• Associations between fluid biomarkers and PET imaging ([ 11 C]UCB-J) of synaptic pathology in Alzheimer’s disease

  2025cites this paper
• Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

  2025cites this paper
• The associations of cerebrospinal fluid ApoE and C1q with Alzheimer's disease biomarkers

  2025cites this paper
• Comparison of Deep Learning and Traditional Machine Learning Models for Predicting Mild Cognitive Impairment Using Plasma Proteomic Biomarkers

  2025cites this paper
• Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease

  2025cites this paper
• Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency

  2025cites this paper
• Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease.

  2025cites this paper
• Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases

  2024cites this paper
• Serum Oxidative Stress-related Biomarkers in Ocular Hypertension and Glaucoma

  2024cites this paper
• ADNI Biomarker Core: A review of progress since 2004 and future challenges

  2024cites this paper
• Involvement of the VGF/BDNF axis in the neuropathology of Alzheimer’s disease and its potential role in diagnosis and treatment

  2024cites this paper
• Analysis of Brain Protein Stability Changes in a Mouse Model of Alzheimer's Disease.

  2024cites this paper
• Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine

  2024cites this paper
• Osteopontin: A novel marker of pre‐symptomatic sporadic Alzheimer's disease

  2024cites this paper
• Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment

  2024cites this paper
• Associations of cerebrospinal fluid complement proteins with Alzheimer’s pathology, cognition, and brain structure in non-dementia elderly

  2024cites this paper
• Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer

  2024cites this paper
• Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer

  2024cites this paper
• Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia

  2024cites this paper
• Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

  2024cites this paper
• Cerebrospinal Fluid Complement 4 Levels Were Associated with Alzheimer’s Disease Pathology and Cognition in Non-Demented Elderly

  2023cites this paper
• Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD

  2023cites this paper
• Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

  2023influential citation
• E. coli outer membrane protein T (OmpT) nanopore for peptide sensing.

  2023cites this paper
• Anxiety adds the risk of cognitive progression and is associated with axon/synapse degeneration among cognitively unimpaired older adults

  2023cites this paper
• NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment

  2023cites this paper
• Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease

  2023cites this paper
• Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer’s disease biomarkers

  2023cites this paper
• White matter hyperintensity volume modifies the association between CSF vascular inflammatory biomarkers and regional FDG-PET along the Alzheimer's disease continuum.

  2023cites this paper
• Improving the Robustness of Variable Selection and Predictive Performance of Regularized Generalized Linear Models and Cox Proportional Hazard Models

  2023cites this paper
• Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

  2022cites this paper
• Analysing and Evaluating Complementarity of Multi-Modal Data Fusion in AD Diagnosis

  2022cites this paper
• CSF proteomic signature predicts progression to Alzheimer's disease dementia

  2022cites this paper
• Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

  2022cites this paper
• Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders

  2022cites this paper
• Sex differences in Alzheimer’s disease: plasma MMP-9 and markers of disease severity

  2022cites this paper
• Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€TMs disease CSF profile of neuronal injury and inflammation

  2022cites this paper
• Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry

  2022cites this paper
• Sequestration of TDP-43216-414 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone.

  2022cites this paper
• Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders

  2022cites this paper
• Pro-inflammatory cytokines in aqueous humor from dogs with anterior uveitis and post-operative ocular hypertension following phacoemulsification, primary glaucoma, and normal healthy eyes

  2022cites this paper
• Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

  2022cites this paper
• Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

  2022influential citation
• Neurotrophin Crosstalk in the Etiology and Treatment of Neuropsychiatric and Neurodegenerative Disease

  2022cites this paper
• VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders.

  2022cites this paper
• Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

  2021cites this paper
• Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways

  2021cites this paper
• Proteome profiling of neuron-derived exosomes in Alzheimer's disease reveals hemoglobin as a potential biomarker.

  2021cites this paper
• Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease

  2021cites this paper
• Regional relationships between CSF VEGF levels and Alzheimer's disease brain biomarkers and cognition.

  2021cites this paper
• Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids

  2021influential citation
• Rare variants in IFFO1, DTNB and NLRC3 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation

  2021cites this paper
• Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42.

  2021influential citation
• CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals

  2021cites this paper
• Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration

  2021cites this paper
• Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer's disease

  2021cites this paper
• Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimer’s Disease Patients: Getting Clues from Proteomic Studies

  2021cites this paper
• The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives

  2021cites this paper
• An Ensemble-Learning Based Application to Predict the Earlier Stages of Alzheimer’s Disease (AD)

  2020influential citation
• Exploring the Potential of Neuroproteomics in Alzheimer's Disease.

  2020cites this paper
• Sequestration of TDP-43216-414 aggregates by cytoplasmic expression of the proSAAS chaperone

  2020cites this paper
• Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

  2020cites this paper
• APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

  2020cites this paper
• SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer’s disease

  2020cites this paper
• Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

  2020cites this paper
• Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid.

  2020cites this paper
• The VGF-derived Peptide TLQP21 Impairs Purinergic Control of Chemotaxis and Phagocytosis in Mouse Microglia

  2020cites this paper
• VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice

  2020cites this paper
• Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics

  2020cites this paper
• A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease

  2020cites this paper
• Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology

  2020cites this paper
• APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid

  2020cites this paper
• Increased expression and retention of the secretory chaperone proSAAS following cell stress

  2020cites this paper
• Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease

  2020cites this paper
• Secreted Chaperones in Neurodegeneration

  2020cites this paper
• Fluid Biomarkers for Synaptic Dysfunction and Loss

  2020cites this paper
• Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis

  2020cites this paper
• The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models

  2020cites this paper
• Cerebrospinal fluid tau levels indicate aberrant neuronal plasticity in Alzheimer disease

  2020cites this paper
• Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2020cites this paper
• Low Cerebrospinal Fluid Levels of Hemopexin Are Associated With Increased Alzheimer's Pathology, Hippocampal Hypometabolism, and Cognitive Decline

  2020cites this paper
• Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

  2019cites this paper
• VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer’s Disease

  2019cites this paper
• Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance.

  2019cites this paper
• Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer’s Disease Progression that Reinforces the 2018 NIA-AA Research Framework

  2019cites this paper
• Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics

  2019influential citation